Durable B-ALL Control With Allogeneic Transplant After CAR T-Cell Therapy
Investigators sought to assess outcomes following CD19 CAR T-cell therapy in children and young adults who underwent alloHSCT for B-cell acute lymphoblastic leukemia.
Acute Lymphoblastic Leukemia
Blinatumomab Improves Outcomes in Children With High-Risk B-ALL
A multicenter, randomized, phase 3 trial compared blinatumomab with intensive multidrug consolidation chemotherapy in children with high-risk, first-relapse B-cell ALL.
Measurable Residual Disease Is Prognostic Factor Before Transplantation in First and Second Remission of Ph+ ALL
A team of investigators evaluated the effect of measurable residual disease at time of allogeneic hematopoietic cell transplantation in patients with ALL undergoing transplantation during either first or second complete remission.
Tocilizumab for Cytokine Release Syndrome With CTL019 in Pediatric B-ALL
Open-label, prospective study investigated the effects of preemptive administration of tocilizumab in pediatric patients with B-ALL undergoing CAR-T therapy.
Total Body Irradiation vs Chemotherapy Conditioning for Pediatric Acute Lymphoblastic Leukemia
Investigators compared outcomes of chemotherapy conditioning with total body irradiation prior to hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Addition to Supportive Care Documentation Decreased AE Risks Associated With High-Dose Methotrexate
Incorporating 2 standardized documents into the process for supportive care measures improved outcomes for patients receiving HD-MTX.
Postmarketing Observational Study of Tisagenlecleucel for ALL or NHL Yields Promising Results
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
Nelarabine for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
Young patients with newly diagnosed T-cell acute lymphoblastic leukemia showed favorable outcomes with nelarabine added to a treatment regimen.
Genetic Predisposition for Thromboembolism in Adolescent Acute Lymphoblastic Leukemia
As thromboembolism is a common side effect of ALL treatment, investigators assessed whether its occurrence in ALL and in the general adult population have a shared genetic basis.
Development of a Tool to Predict Neurotoxicity Associated With CAR-T Therapy
The occurrence, severity, and need for treatment of cytokine release syndrome were key parameters in the assessment of CAR-T–related neurotoxicity risk.
-
Loading...
-
Loading...
Next post in Hematologic Cancers
